Follicum receives European patent for the company's peptides for developing first in class diabetes treatments
Follicum AB today announces that the European Patent Office (EPO) has approved the patent EP 3 618 845 B1, which refers to the company's novel peptides that are being developed to treat diabetes. The approval follows the previous provisional approval by the EPO announced on March 20, 2020.The approval by the EPO of patent No. EP 3,618,845 B1 provides protection for the company's peptides and their use to treat diabetes in Europe until 2038. Similar patents have previously been approved in the United States. In addition, Follicum has a corresponding patent application under review by